Reduced‐dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta‐analysis

Essentials In venous thromboembolism (VTE), benefits of extended treatment are balanced by bleeding risks. This is a meta‐analysis of reduced‐dose direct oral anticoagulants (DOACs) in extended treatment. Reduced‐dose DOACs are as effective as full anticoagulation with bleeding risks similar to placebo. Reduced‐dose DOACs are an attractive option for patients in the extended phase of VTE treatment.

[1]  M. Prins,et al.  Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism , 2017, The New England journal of medicine.

[2]  H. Büller,et al.  Deep vein thrombosis and pulmonary embolism , 1993, The Lancet.

[3]  P. Sandset,et al.  Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH , 2016, Journal of thrombosis and haemostasis : JTH.

[4]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[5]  P. Prandoni,et al.  Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration , 2014, Circulation.

[6]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[7]  Chris Cameron,et al.  Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis , 2013, BMJ.

[8]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[9]  G. Raskob,et al.  Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[10]  F. García-Bragado Dalmau.  [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.

[11]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[12]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[13]  R. Gans,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.

[14]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[15]  A. Iorio,et al.  Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. , 2010, Archives of internal medicine.

[16]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[17]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[18]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[19]  M. Gent,et al.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[20]  I Iturralde,et al.  Deep vein thrombosis and pulmonary embolism , 1990 .